Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Hachulla

Showing results (321-330 of 346) with videos related to

Pageof 35
Sort By:
Arthritis and Rheumatism|August 1, 2009
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosisP Dieudé, M Guedj, J Wipff, et al.
Lupus|July 19, 2018
Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndromeC M Yelnik, M Lambert, E Drumez, et al.
Arthritis and Rheumatism|January 7, 1998
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosisL Guillevin, J F Cordier, F Lhote, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian populationP Dieudé, M Guedj, J Wipff, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2019
Early-onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndromeJ Poline, O Fogel, C Pajot, et al.
Clinical Immunology (Orlando, Fla.)|August 21, 2018
Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patientsA C Desbois, L Biard, O Addimanda, et al.
Annals of the Rheumatic Diseases|August 24, 2011
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypesJasmin B Kuemmerle-Deschner, E Hachulla, R Cartwright, et al.
Annales De Medecine Interne|January 1, 1996
Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patientsP Cohen, Q T Nguyen, P Dény, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Pageof 35

Showing results (321-330 of 346) with videos related to

Sort By:
Pageof 35
Arthritis and Rheumatism|August 1, 2009
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosisP Dieudé, M Guedj, J Wipff, et al.
Lupus|July 19, 2018
Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndromeC M Yelnik, M Lambert, E Drumez, et al.
Arthritis and Rheumatism|January 7, 1998
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosisL Guillevin, J F Cordier, F Lhote, et al.
Annals of the Rheumatic Diseases|June 1, 2010
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian populationP Dieudé, M Guedj, J Wipff, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 22, 2019
Early-onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndromeJ Poline, O Fogel, C Pajot, et al.
Clinical Immunology (Orlando, Fla.)|August 21, 2018
Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patientsA C Desbois, L Biard, O Addimanda, et al.
Annals of the Rheumatic Diseases|August 24, 2011
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypesJasmin B Kuemmerle-Deschner, E Hachulla, R Cartwright, et al.
Annales De Medecine Interne|January 1, 1996
Treatment of mixed cryoglobulinemia with recombinant interferon alpha and adjuvant therapies. A prospective study on 20 patientsP Cohen, Q T Nguyen, P Dény, et al.
Arthritis and Rheumatism|October 31, 2009
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4P Dieudé, J Wipff, M Guedj, et al.
The British Journal of Dermatology|October 9, 2012
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialS Prey, K Ezzedine, A Doussau, et al.
Pageof 35